Search results for "Pancreatic neoplasms"

showing 10 items of 191 documents

Non-arbitrary minimum threshold of yearly performed pancreatoduodenectomies: National multicentric study

2021

Abstract Background Annual hospital volume of pancreatoduodenectomies could influence postoperative outcomes. The aim of this study is to establish with a non-arbitrary method the minimum threshold of yearly performed pancreatoduodenectomies in order to improve several postoperative quality outcomes. Method Prospective follow-up of patients submitted to pancreatoduodenectomy in participating hospitals during 1 year. The influence of hospital volume on quality outcomes was analyzed by univariable and multivariable models. The minimum threshold of yearly performed pancreatoduodenectomies to improve outcomes was established by Akaike’s information criteria. Results Data from 877 patients opera…

AdultMalemedicine.medical_specialtyPostoperative death030230 surgeryPancreaticoduodenectomyYoung Adult03 medical and health sciencesPostoperative Complications0302 clinical medicineHospital volumeRisk FactorsmedicineHumansAgedQuality of Health CareAged 80 and overbusiness.industryMargins of ExcisionLength of StayMiddle AgedHospitalsPancreatic NeoplasmsSpain030220 oncology & carcinogenesisMultivariate AnalysisEmergency medicineLymph Node ExcisionFemaleSurgerybusinessSurgery
researchProduct

Clinical outcome of patients who underwent total pancreatectomy.

2010

non disponibile

AdultMalemedicine.medical_specialtyTotal pancreatectomyEndocrinology Diabetes and MetabolismMEDLINEOutcome assessmentOutcome (game theory)EndocrinologyQuality of life (healthcare)CognitionPancreatectomytotal pancreatectomy.Health careOutcome Assessment Health CareInternal MedicinemedicineHumansPancreasAgedHepatologybusiness.industryGeneral surgeryMiddle AgedPancreatic NeoplasmsQuality of LifeFemalebusinessPancreas
researchProduct

Whipple's pancreaticoduodenectomy: Surgical technique and perioperative clinical outcomes in a single center

2015

Abstract Introduction Pancreatic cancer is the fourth cause of death from cancer in Western countries. The radical surgical resection is the only curative option for this pathology. The prevalence of this disease increases with age in population. The causes of pancreatic cancer are unknown, but we consider risk factors like smoke and tobacco usage, alcohol consumption coffee, history of diabetes or chronic pancreatitis. In this study we report our experience in the treatment of resectable pancreatic cancer and periampullary neoplasms with particular attention to evaluate the evolution of surgical technique and the clinical postoperative outcomes. Methods In our Department between January 20…

AdultMalemedicine.medical_specialtyWhipple proceduremedicine.medical_treatmentPopulationPancreaticoduodenectomyPancreatic FistulaPancreatectomyPostoperative ComplicationsRisk FactorsPancreatic cancerMedicineHumanseducationAgedAged 80 and overeducation.field_of_studyGastric emptyingbusiness.industryClinical outcomePostoperative pancreatic fistulaGeneral surgeryAnastomosis SurgicalCancerGeneral MedicinePerioperativePancreatic cancerLength of StayMiddle AgedPancreaticoduodenectomymedicine.diseaseSurgeryPancreatic NeoplasmsClinical outcomes; Pancreatic cancer; Pancreaticoduodenectomy; Postoperative pancreatic fistula; Whipple procedure; SurgerySettore MED/18 - Chirurgia GeneralePancreatic fistulaPancreatitisFemaleSurgerybusinessSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Factors Influencing Morbidity and Mortality after Pancreaticoduodenectomy: Critical Analysis of 221 Resections

1999

A critical analysis of morbidity and mortality for pancreatico-duodenectomy was performed on 221 patients. During the 1960s and 1970s, the morbidity and mortality for pancreaticoduodenectomy were so high that many thought the operative procedure ought to be abandoned. During the 1980s, however, many centers reported mortality rates around 5% and a morbidity of 25% to 35%. Others still reported a mortality of more than 10% and a morbidity of up to 65%. The reasons for these discrepancies are of major interest. In a prospective case-control study 760 patients with malignant and benign diseases of the pancreas were treated in our hospital between September 1, 1985 and April 30, 1997. In 221 ca…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentBlood Loss SurgicalPancreaticoduodenectomyPostoperative ComplicationsmedicineHumansProspective StudiesSurvival rateAgedAged 80 and overPancreatic ductPortal Veinbusiness.industryPatient SelectionGeneral surgeryMortality ratePancreatic DuctsPancreatic DiseasesBilirubinMiddle AgedVascular surgeryPancreaticoduodenectomyCardiac surgerySurgeryPancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureCardiothoracic surgeryCase-Control StudiesRegression AnalysisFemaleSurgeryClinical CompetencebusinessFollow-Up StudiesAbdominal surgeryWorld Journal of Surgery
researchProduct

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Tr…

2021

PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over gemcitabine for overall survival. The high limiting oxaliplatin-related neurotoxicity supports the evaluation of an oxaliplatin stop-and-go strategy and a sequential strategy in mPC. METHODS In this phase II study, patients were randomly assigned to receive either 6 months of FOLFIRINOX (arm A), 4 months of FOLFIRINOX followed by leucovorin plus fluorouracil maintenance treatment for controlled patients (arm B), or a sequential treatment alternati…

AdultOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentFirst lineLeucovorinIrinotecan03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsMetastatic pancreatic cancermedicineHumansNeoplasm MetastasisAgedChemotherapybusiness.industryMiddle Agedmedicine.diseaseOxaliplatinPancreatic NeoplasmsOncologyFluorouracil030220 oncology & carcinogenesisQuality of Life030211 gastroenterology & hepatologyFluorouracilbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis

1980

In 21 patients who had undergone total pancreatectomy for pancreatic head carcinoma, the uninvolved pancreas was examined with regard to the type, incidence and regional distribution of duct epithelial proliferation. The results were compared with those in 37 operative specimens from patients with chronic pancreatitis, in 46 normal pancreases from autopsies and with findings in experimental pancreatic carcinogenesis. While the incidence of squamous metaplasia and non-papillary epithelial hypertrophy varied little in the different groups, papillary epithelial hyperplasia was found three times more often in cases of carcinoma, with associated mild duct obstruction. Atypical epithelial prolife…

Adultmedicine.medical_specialtyNitrosaminesHistologyGastroenterologyPathology and Forensic MedicinePancreatectomyCricetinaeInternal medicineCarcinomamedicineAnimalsHumansMolecular BiologyPancreatic ductAtypical small acinar proliferationHyperplasiamedicine.diagnostic_testbusiness.industryPancreatic DuctsCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseSquamous metaplasiaPancreatic Neoplasmsmedicine.anatomical_structurePancreatitisChronic DiseasePancreatitisFemaleCA19-9AnatomyPancreasbusinessDuct (anatomy)Virchows Archiv A Pathological Anatomy and Histology
researchProduct

Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma

2018

Objective Ampulla of Vater carcinoma (AVC) has a broad spectrum of different prognoses. As such, new moderators of survival are urgently needed. We aimed at clarifying the prognostic role of perineural invasion in AVC. Methods Using PubMed and SCOPUS databases, we conducted the first systematic review and meta-analysis on this topic. Results Analyzing 29 articles for a total of 2379 patients, we found that the presence of perineural invasion increased the risk of all-cause mortality more than 2 times (relative risk [RR], 2.07; 95% confidence interval [CI], 1.78-2.42 [P < 0.0001]; hazard ratio [HR], 2.72; 95% CI, 1.86-3.97 [P < 0.0001]), of cancer-specific mortality more than 6 times (…

Ampulla of Vatermedicine.medical_specialtyEndocrinology Diabetes and MetabolismPNIPerineural invasionPerineumGastroenterology03 medical and health sciencesBroad spectrum0302 clinical medicineEndocrinologypapilla PNI perineural VaterRisk FactorsInternal medicineInternal MedicinemedicineCarcinomaHumansNeoplasm InvasivenessVaterpapillaHepatologybusiness.industryHazard ratioAmpulla of VaterPrognosismedicine.diseaseConfidence intervalPancreatic Neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisRelative riskMeta-analysisperineural030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessCarcinoma Pancreatic DuctalPancreas
researchProduct

Antibody Induction Directed against the Tumor-Associated MUC4 Glycoprotein

2015

Mucin glycoproteins are important diagnostic and therapeutic targets for cancer treatment. Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein. MUC4 is an important tumor marker overexpressed in lung cancer and uniquely expressed in pancreatic ductual adenocarcinoma. The aberrant glycosylation of MUC4 in tumor cells results in an exposure of its peptide backbone and the formation of tumor-associated glycopeptide antigens. Due to the low immunogenicity of these endogenous structures, their conjugation with immune stimulating peptide or prot…

Antibodies NeoplasmMolecular Sequence DataCancer VaccinesBiochemistryEpitopeEpitopesMiceAntigenAntibody SpecificityCell Line TumorTetanus ToxoidAnimalsHumansAmino Acid SequenceMolecular BiologyMUC1chemistry.chemical_classificationMice Inbred BALB CMucin-4biologyImmune SeraImmunogenicityVaccinationOrganic ChemistryToxoidGlycopeptidePancreatic NeoplasmschemistryTandem Repeat SequencesImmunologybiology.proteinMolecular MedicineFemalesense organsAntibodyGlycoproteinChemBioChem
researchProduct

GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutra…

2021

Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link between KRas and GSK-3. To further elucidate the roles of GSK-3β in drug-resistance, we transfected KRas-dependent MIA-PaCa-2 pancreatic cells with wild-type (WT) and kinase-dead (KD) forms of GSK-3β. Transfection of MIA-PaCa-2 cells with WT-GSK-3β increased their resistance to various chemotherapeutic drugs and certain small molecule inhibitors. Transfection of cells with KD-GSK-3β often increased therapeutic sensitivity. An exception was observed wi…

Berberineendocrine system diseasesmedicine.medical_treatmentRegulatormedicine.disease_causeDeoxycytidinePiperazinesTargeted therapychemotherapeutic drugsTargeted therapyNitrophenolsBreast cancerGSK-3BGlycolysisMolecular Targeted TherapyNeoplasm Metastasistargeted therapy;lcsh:QH301-705.5Tumor Stem Cell AssaySulfonamidesTumorbiologyChemistryGeneral MedicineTransfectionMetforminDisease ProgressionMCF-7 CellsFemaleKRASNutraceuticalsFluorouracilSignal transductionGlycolysisSignal TransductionBCL2bcl-X ProteinAntineoplastic AgentsBreast Neoplasmsmacromolecular substancesAdenocarcinomaArticleCell LineInhibitory Concentration 50Cell Line TumorThiadiazolesmedicineDiabetes MellitusKRasHumansGlycogen synthaseProtein Kinase InhibitorsCell ProliferationChemotherapeu-tic drugsGlycogen Synthase Kinase 3 betaGSK-3βAdenylate KinaseBiphenyl Compoundsnutraceuticals;PDACβ-cateninGemcitabine?-cateninMalariaPancreatic Neoplasmslcsh:Biology (General)MCF-7DoxorubicinDietary SupplementsCancer researchbiology.protein
researchProduct

Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole …

2019

Heterocyclic rings are recognized as key components of many natural, semi-synthetic and synthetic molecules with a broad spectrum of biological activities. Among these molecules, the indole and imidazo[2,1-b][1,3,4]thiadiazole systems have recently been described as useful scaffolds for the design of anticancer agents. Herein the antitumor activity of a series of 3-(6-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indoles, designed as hybrid structures, was assessed. Seven out of 10 compounds (1a-g) were submitted to National Cancer Institute (NCI). Remarkably, compound 1g showed antiproliferative activity against the full panel of sixty human cancer lines, with half-maximal inhibitory conc…

Cancer Research3Stereochemistry1-b][1Indole systemAntineoplastic Agent03 medical and health sciences0302 clinical medicine4]thiadiazole derivativeCell MovementCell Line TumorPancreatic cancermedicineImidazo[2Cell ProliferationBiological evaluationAntitumor activityIndole testChemistryCancerAnti-migratory activityPancreatic cancerGeneral Medicinemedicine.diseaseIn vitroPancreatic NeoplasmsOncologyIndolePancreatic cancer cell030220 oncology & carcinogenesisAnti-proliferative activityHuman cancerHuman
researchProduct